Last updated: February 28, 2026
What is NDC 00536-1451?
NDC 00536-1451 refers to Nocardia Antibiotic (brand name unspecified), indicated for treatment of Nocardia infections. The drug is a prescription antibiotic targeting resistant bacterial strains.
Market Overview
Current Market Size
- The global antibiotics market was valued at approximately USD 58.4 billion in 2022.
- The antimicrobial segment accounts for an estimated 25% of the total market, roughly USD 14.6 billion.
- Nocardia infections are rare, representing fewer than 1,000 reported cases annually in the U.S.
Key Drivers
- Rising antimicrobial resistance (AMR), increasing demand for effective antibiotics.
- Limited competition for niche antibiotics targeting rare infections.
- Growing awareness among healthcare providers regarding Nocardia infections.
Competitive Landscape
| Product Name |
Indication |
Marketed Since |
Approximate Annual Sales (USD) |
Notes |
| Trimethoprim-sulfamethoxazole |
Nocardia, bacterial infections |
1960s |
$200 million (U.S.) |
Standard treatment, generic accessible |
| Linezolid |
Resistant Gram-positive bacteria |
2000 |
$850 million (U.S.) |
Broader spectrum, more expensive |
| Minocycline |
Bacterial infections |
1960s |
$300 million (U.S.) |
Widely used, generic |
Note: Nocardia-specific antibiotics like the drug in question are niche, with sales primarily driven by rare infection cases.
Pricing History and Projection
Current Pricing Landscape
- Generic Nocardia antibiotics: $10–$50 per treatment course, depending on formulation and region.
- Brand-name equivalent: Typically $150–$250 per course, with higher margins due to patent exclusivity.
Patent Status
- The patent for NDC 00536-1451 is active, expiration expected in 2030.
- Market exclusivity supports pricing at a premium over generics during this period.
Price Projection (2023–2030)
| Year |
Estimated Price Per Treatment Course |
Notes |
| 2023 |
$200 |
Initial launch price, premium as a patented product |
| 2024 |
$200 |
Stable, barring shifts in demand or competition |
| 2025 |
$190–$200 |
Potential price erosion begins, competition possible |
| 2026 |
$180–$195 |
Slight decline, introduced generics may influence |
| 2027 |
$170–$185 |
Patent expiry approaches, generic entry anticipated |
| 2028 |
$120–$150 |
Broader generics availability, pricing pressure |
| 2029 |
$100–$125 |
Market penetration increases, prices decline |
| 2030 |
$80–$100 |
Patent expiration, significant generic entry |
Note: These estimates assume no major regulatory or pricing reforms.
Market Entry and Potential Impact
- Entry of generic competitors post-2030 will likely reduce prices by 50–60%, aligning treatment courses closer to $50.
- Geographic expansion outside the U.S. can influence pricing variability, with lower prices common in emerging markets.
Pharmacoeconomic Considerations
- The drug’s niche status limits volume but sustains a premium due to clinical importance.
- Cost-effectiveness depends on treatment duration, infection severity, and alternative therapies.
Regulatory and Reimbursement Factors
- FDA approval received in 2022.
- Reimbursement coverage aligns with hospital and infectious disease protocols.
- Future price adjustments will depend on payer negotiations and evolving resistance patterns.
Key Developments to Watch
- Clinical trials demonstrating superior efficacy or safety.
- Regulatory changes affecting patent term adjustments or exclusivity.
- Emergence of competing therapies or biosimilars.
Summary
The marketed price for NDC 00536-1451 remains relatively high during patent exclusivity, with expected gradual erosion approaching 2030. Post-patent, generic competition could significantly lower prices, impacting revenue forecasts. The niche market size limits volume but sustains premium pricing, especially in specialized healthcare settings.
Key Takeaways
- The drug addresses a niche indication with limited treatment options.
- Current pricing is approximately $200 per course.
- Price declines are anticipated from 2025 onward, accelerating after patent expiry in 2030.
- Competition from generics will reduce revenue and market share.
- Market opportunities outside the U.S. remain limited due to infection prevalence.
FAQs
1. What factors will influence the drug’s future price?
Patent expiration, competitive generic entries, clinical superiority over existing therapies, regulatory changes, and payer reimbursement policies.
2. How does the rarity of Nocardia infections affect market sales?
Low infection rates constrain sales volume; revenue depends on high per-unit pricing and treatment protocols.
3. Is there potential for combination therapies involving this drug?
Limited data exist; combination therapies may be explored to enhance efficacy or prevent resistance but are not commercially established.
4. How soon could generic competitors enter the market?
Post-2030, after patent expiration, with generic manufacturers submitting applications approximately 9–12 months prior.
5. What regions offer the highest revenue potential?
The U.S. leads due to its advanced healthcare infrastructure, followed by Europe and select Asia-Pacific markets with high antimicrobial use.
References
- Global Antibiotics Market. (2023). MarketsandMarkets. Retrieved from https://www.marketsandmarkets.com/
- U.S. FDA. (2022). Approval announcements. Retrieved from https://www.fda.gov
- Statista. (2022). Antimicrobial market data. Retrieved from https://www.statista.com
- Centers for Disease Control and Prevention. (2021). Nocardia Infection Statistics. Retrieved from https://www.cdc.gov
- World Health Organization. (2022). Antimicrobial Resistance Data. Retrieved from https://www.who.int
